Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook | Compelling sustainability story
B Maximizing near-term Biosimilars launches
14
Targeted
brand
Therapeutic
areas
Originator net
sales targeted¹
HumiraⓇ
Immunology
~ USD 21bn
adalimumab²
TysabriⓇ
natalizumab
Neurology /
Immunology
~ USD 2bn
ProliaⓇ / XgevaⓇ Bone diseases
~ USD 7bn
denosumab
/ Oncology
EyleaⓇ
Ophthalmology
~ USD 11bn
aflibercept
StelaraⓇ
Immunology
~ USD 10bn
ustekinumab
Key
highlights
High Concentration Formulation (HCF),
proven supply reliability and strong cost
position, differentiating features
First and potentially only Biosimilar to
market, leveraging experience from
Omnitrope success
Most advanced industry program,
market expansion opportunity in
Osteoporosis
Strong target product profile,
including prefilled syringe at launch
Exclusive commercialization rights
in Europe and North America
Current
status
HyrimozⓇ launched in the US
since July 1, 2023
EU launch expected in H2 2023
FDA approval and positive
CHMP opinion received
Expected FDA approval in
Q4 2023 and filed in the EU
May 2023
Filing in the US and EU
expected in the coming
months
Phase III completed in
November 2022
Note: The third-party trademarks above are property of their respective owners, 1. Originator sale covered based on Company analysis using Evaluate Pharma; at full year prior to expected market formation year 2. Only pertains to adalimumab
high concentration formulation (HCF)
SANDOZView entire presentation